Sjögren's disease & overlap diseases

Prevalence, incidence and mortality of interstitial lung disease in patients with Sjogren disease: data from the prospective observational “EMERGE” study

Semin Arthritis RheumPublished Prospective cohort study

Authors' conclusion

ILD can be identified in a high number of SjD patients, inducing a significant impairment in survival. The ILD extent, but not HRCT pattern of ILD, represents the main predictor of mortality.

Study context

Population
Unselected consecutive Sjögren disease (SjD) patients referred to the centre
Participants
257 patients
Exposure
SjD patients with vs without interstitial lung disease (ILD)
  • ILDn = 61
Outcome
Prevalence, incidence and mortality of SjD-ILD
Methodological detailsobservational, consecutive patients, single-centre
  • Observational
  • Consecutive patients
  • Single-centre

Main finding

As reported in the abstract

Prevalence of ILD at enrolment

ILD prevalence (61/257)

23.7 %

ILD incidence, new cases per 100 patients/year (3 new cases)

0.41

Observational data: associations, not effects.

Further findings

OutcomeILDWithout ILDP value
Overall survival · mean follow-up 42.6 ± 14.6 months66.5 % ± 11.788.4 % ± 5.5P < 0.001
Overall survival — Deaths during follow-up (21 patients)
8.2 %

Factors associated with ILD (multivariate)

Direct association with male sex, age at SjD diagnosis and ESR >40 mm; inverse with sicca syndrome

Predictors of mortality

Fibrotic pattern associated with worse survival; no difference by radiologic pattern
Anti-SSA protective; age at SjD diagnosis and ILD extent at high-resolution computed tomography (HRCT) associated with increased mortality

Original publication

Prevalence, incidence and mortality of interstitial lung disease in patients with Sjogren disease: data from the prospective observational “EMERGE” study. Semin Arthritis Rheum. Published 22 November 2025. doi:10.1016/j.semarthrit.2025.152886

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.